Scholars Central

Conference abstractPublished 29 Nov 2011

Neural stem cellsmediated therapy of amyotrophic lateral sclerosis

Authors: Lidia De Filippis

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive degeneration of motor neurons which leads to defi nitive muscular paralysis and fi nally to respiratory failure. We have previously shown that NSC are able to delay motor neuron degeneration aft er injection into the spinal cord of EAE multiple sclerosis mice model, to boost endogenous remyelination in the corpus callosum of focally demyelinated rats and to dampen microgliosis and astrogliosis into the ischemic brain of adult. Th ese results together with studies from other labs showing the effi cacy of neural precursors to delay ALS progression when transplanted into the spinal cord of ALS rodents have promoteD NSC transplantation as a therapeutic strategy. Moreover, cell therapy is reaching the stage of clinical application, with the fi rst few clinical trials already underway in some post traumatic, post-ischemic or neurodegenerative disorders. A standardized, clinical grade source of normal human CNS cells (hNSCs), combining the plasticity of foetal tissue with extensive proliferative capacity and functional stability would be of paramount importance in this fi eld. We established continuous and stable hNSC lines from the foetal CNS and showed their ability to integrate in the spinal cord of ALS animal model aft er transplantation. We are currently investigating some of the NSC-mediated therapeutic eff ects, such as trophic support to host cells and immunomodulation of the infl ammatory environment. It has to be emphasized that hNSC lines were grown according rules of Good Manufacturing Practices (GMP) in medium containing EGF and b-FGF according to the neurosphere assay paradigm and they have been recently approved by the Italian Agency of Pharmacology (AIFA) for clinical trial phase I on ALS patients.

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cell Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Science & Therapy
  • SubjectBiology
  • BylineArticles whose byline prints “Lidia De Filippis”